Authors Tang X, Pu Y, Peng H, Li K, Faouzi S, Lu T, Pu D, Cerezo M, Xu J, Li L, Robert C, Shen S
Computational and structural biotechnology journal Feb 2023
From normal hematopoiesis to malignancies: Highlights from the 2021 Meeting of the Club Hematopoiesis and Oncogenesis.Authors Troadec MB, Porteu F, Arcangeli ML, Foudi A, Bluteau D, De Sepulveda P, Guillouf C, Mazure NM, Meggetto F, Brunet De La Grange P, Broccardo C
Bulletin du cancer Feb 2023
Repurposing the Bis-Biguanide Alexidine in Combination with Tyrosine Kinase Inhibitors to Eliminate Leukemic Stem/Progenitor Cells in Chronic Myeloid Leukemia.Authors Muselli F, Mourgues L, Rochet N, Nebout M, Guerci A, Verhoeyen E, Krug A, Legros L, Peyron JF, Mary D
Cancers Feb 2023
The mechanical phenotypic plasticity of melanoma cell: an emerging driver of therapy cross-resistance.Authors Diazzi S, Tartare-Deckert S, Deckert M
Oncogenesis Feb 2023
Novel Therapeutic Targets in Melanoma.Authors Cerezo M, Rocchi S
Cancers Feb 2023
IL-7 germline variant: setting the stage for immune-related adverse events.Authors Issaoui H, Ricci JE
Molecular oncology Feb 2023
The mechanosensitive TRPV2 calcium channel promotes human melanoma invasiveness and metastatic potential.Authors Shoji KF, Bayet E, Leverrier-Penna S, Le Devedec D, Mallavialle A, Marionneau-Lambot S, Rambow F, Perret R, Joussaume A, Viel R, Fautrel A, Khammari A, Constantin B, Tartare-Deckert S, Penna A
EMBO reports Feb 2023
MCB-613 exploits a collateral sensitivity in drug resistant -mutant non-small cell lung cancer through covalent inhibition of KEAP1.Authors Bassil CF, Anderson GR, Mayro B, Askin KN, Winter PS, Gruber S, Hall TM, Hoj JP, Cerda-Smith C, Hutchinson HM, Killarney ST, Singleton KR, Qin L, Jubien-Girard K, Favreau C, Martin AR, Robert G, Benhida R, Auberger P, Pendergast AM, Lonard DM, Puissant A, Wood KC
bioRxiv : the preprint server for biology Jan 2023
High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia.Authors Aid Z, Robert E, Lopez CK, Bourgoin M, Boudia F, Le Mene M, Riviere J, Baille M, Benbarche S, Renou L, Fagnan A, Thirant C, Federici L, Touchard L, Lecluse Y, Jetten A, Geoerger B, Lapillonne H, Solary E, Gaudry M, Meshinchi S, Pflumio F, Auberger P, Lobry C, Petit A, Jacquel A, Mercher T
Leukemia Dec 2022
Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade.Authors Nazerai L, Willis SC, Yankilevich P, Di Leo L, Bosisio FM, Frias A, Bertolotto C, Nersting J, Thastrup M, Buus S, Thomsen AR, Nielsen M, Rohrberg KS, Schmiegelow K, De Zio D
Oncoimmunology Dec 2022